Case Reports in Dermatological Medicine
Volume 2014 (2014), Article ID 938414, 6 pages
http://dx.doi.org/10.1155/2014/938414

Case Report

Diffuse Cutaneous Mucinosis in Dermatomyositis: A Case Report and Review of the Literature

Alexandra Caitlin Perel-Winkler¹ and Chris T. Derk²

¹St. Luke’s-Roosevelt Hospital Center, New York, NY 10025, USA
²Division of Rheumatology, University of Pennsylvania, One Convention Boulevard, 8th Floor Penn Tower, Philadelphia, PA 19104, USA

Received 29 July 2014; Accepted 1 November 2014; Published 18 November 2014

Academic Editor: Ravi Krishnan

Copyright © 2014 Alexandra Caitlin Perel-Winkler and Chris T. Derk. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

We present the case of a patient with dermatomyositis and diffuse cutaneous mucinosis and give an up-to-date detailed review of all the published cases in the English literature describing the demographics, clinical picture, pathology management, and outcomes of this unique group of patients.

1. Introduction

Mucin (hyaluronic acid complex) is a protein normally found as part of the dermal connective tissues and it is produced by mast cells and fibroblasts. As hyaluronic acid holds water, in disease states where mucin production is increased, the dermal connective tissue becomes swollen and is described as myxedematous. It is not uncommon to have findings of microscopic cutaneous mucinosis in the setting of collagen vascular diseases and mucin deposition in the correct clinical setting can be considered as histologic evidence of dermatomyositis (DM) [1]. Clinically evident forms of mucinosis have been described in hypothyroidism, thyrotoxicosis, scleromyxedema associated with monoclonal gammopathies, scleredema related to diabetes, and lichen myxedematosus. Cases of secondary cutaneous mucinosis have been described in systemic lupus erythematosus, systemic sclerosis, and dermatomyositis, albeit infrequently [2–8]. We present a case of dermatomyositis with evidence of diffuse cutaneous mucinosis in a patient recently treated for nonsmall cell lung cancer (NSCLC) without evidence of recurrence.

2. Case

A 57-year-old man with chronic obstructive lung disease, hypothyroidism, gastroesophageal reflux disease, and a prior history of NSCLC developed a pruritic, confluent, violaceous rash after cancer treatment. The patient was diagnosed with NSCLC in 2011 and was treated with paclitaxel and carboplatin and adjunctive radiation, with a restaging PET/CT scan showing excellent response. Four months after the completion of chemotherapy and radiation therapy the patient presented complaining of a pruritic rash. The rash first appeared on his hands and was noted to be consistent with Gottron’s papules. Over the next nine months the rash worsened, and the patient developed violaceous erythema on his upper chest and back. Erythematous patches with white macules then developed on his lower legs, thighs, and buttocks. Three years after the treatment of his cancer, the patient had a diffuse, scaly, and erythematous rash on his arms (Figure 1), legs, buttocks, abdomen, neck, and face (Figure 2) with evidence of white macules (Figure 3) most prominent on the upper and lower extremities. Initial concern was for recurrence of his cancer; however, full body PET-CT revealed no new or active cancer. Skin biopsies showed evidence of interface dermatitis with sections of hyperkeratosis, mild spongiosis, interface vacuolar change, and dermal mucinosis without involvement of the panniculus or fascia (Figures 4 and 5). Muscle enzyme tests showed a normal creatinine phosphokinase level but an elevated aldolase at 9.5 U/L. A later full thickness biopsy performed showed evidence of interface dermatitis with mucin deposition. Two muscle biopsies were performed and HLA1 staining showed diffuse labeling of the sampled myofibers. Only one necrotic myofiber was isolated; otherwise the specimens were largely normal without diffuse myofiber necrosis, inflammation, or definite vacuolation. An MRI of the patient’s femurs showed hyperenhancement in the obturator internus and externus muscles bilaterally and the proximal hamstrings (right greater than left), indicating some degree of inflammation. Immunoserologic results included a positive ANA of 1 : 640 with a speckled pattern and a positive Smith antibody (Ab). Of the myositis autoantibody panel, anti-Ku and anti-U1RNP were found to be positive. Other labs included a normal TSH and a slightly elevated gamma-globulin fraction of 1.7 g/dL (reference range 0.7–1.2 g/dL) with a normal immunofixation.

Figure 1: Cutaneous mucinosis: violaceous, scaly, and erythematous rash of the right arm.

Figure 2: Cutaneous mucinosis: diffuse erythematous, violaceous rash of the face.

Figure 3: Cutaneous mucinosis: diffuse, scaly, and erythematous rash with white macules.

Figure 4: Skin biopsy: colloidal iron with hyaluronidase ×100. Dermal mucin deposition without fibroblast proliferation, with interface vacuolar changes.

Figure 5: Skin biopsy: colloidal iron ×200: dermal mucin depositions without fibroblast proliferation.

Dermatomyositis with cutaneous mucinosis was diagnosed in light of the physical exam findings, MRI evidence of inflammation, evidence of interface dermatitis, and mucin deposition on the skin biopsies and positive serologies. The demonstration of mucinosis without fibroblastic proliferation or dermal thickening supported a diagnosis of cutaneous mucinosis as opposed to scleromyxedema or systemic sclerosis.

Prior to presentation at our clinic, 3 years after the initial symptoms began, the patient had tried multiple medical treatments. He was initially treated with 5 mg of oral prednisone, which was quickly increased to 20 mg without success. Methotrexate was initiated at 7.5 mg weekly and then titrated to 15 mg weekly without response. Plaquenil 200 mg was tried for 2 months but the patient discontinued the treatment as he felt it had no effect. Once we diagnosed the patient with dermatomyositis and diffuse cutaneous mucinosis, we initiated 60 mg of prednisone per day which was tapered to 40 mg daily two weeks later due to side effects. Intravenous Immunoglobulin was initiated at 20 grams for 3 consecutive days every 6 weeks. At 3-month follow-up, the patient reported significant improvement in the amount of erythema and induration especially in the upper extremities and a decrease in the white macular lesions.

3. Discussion

3.1. Dermatomyositis and Cutaneous Mucinosis

Dermatomyositis is an inflammatory myopathy, which affects striated muscle and has cutaneous features. Typically a heliotropic rash, Gottron’s papules, shawl sign, and erythematous plaques are some of the dermatologic manifestations; however, atypical cutaneous features, including plaque like mucinosis, have also been described [1]. The pathophysiology of dermatomyositis includes the expression of autoantibodies which target protein synthesis or translational particles in the muscle cell which triggers a humoral immune response. Activation of proinflammatory cytokines and chemokines leads to the migration of lymphoid cells to the perimysial and endomysial spaces; complement activation leads to the formation and deposition of membranolytic attack complexes onto endomysial capillaries. The result is microangiopathy and necrosis of endothelial cells leading to perivascular inflammation, muscle ischemia, and muscle fiber destruction [8, 13].

Mucin is a mucopolysaccharide produced by fibroblasts and consists of hyaluronic acid and sulfated glycosaminoglycans. Cutaneous mucinosis is subdivided into primary and secondary types; in primary, mucin deposition is the primary histologic feature and secondary, where mucin deposition is an additional finding to a primary clinicopathologic setting. Cutaneous manifestations of mucin can be focal or diffuse and are described as dermal or epidermal (follicular) [9, 14]. The pathophysiology of increased mucin deposition in connective tissue diseases is not completely understood and it is a rare finding. It is postulated that substances circulating in the serum, such as immunoglobulins, autoantibodies, or cytokines, stimulate glycosaminoglycan synthesis by fibroblasts leading to the production of mucin and its deposition in the skin [8, 12]. Pandya et al. linked the increased level of serum autoantibody titres with an increase in mucin lesions in patients with SLE [11, 15]. Interleukin-1 and interleukin-6 have also been shown to be elevated in patients with increased dermal mucin production in SLE and DM; however this is nonspecific as interleukins may be raised without evidence of mucinosis [2].

The concept of a hypoxic state contributing to the increased production of mucin has yet to be considered as part of the pathogenesis in DM. In cases of cutaneous mucinosis reported in the setting of venous insufficiency it has been hypothesized that reduced oxygen tension triggers chondrocytes to increase production of hyaluronic acid [16–18]. With perivascular inflammatory infiltrate, capillary obliteration, and myofiber necrosis as known sequelae of DM pathogenesis, it is conceivable that the biologic milieu of DM is hypoxic, and this may be a contributing factor towards mucin production.

Including our patient, there is a total of 12 cases in the English literature describing macroscopically evident cutaneous mucinosis in the setting of dermatomyositis (Table 1). Of these, three cases were associated with malignancy, and one patient had a history of autoimmune thyroiditis, inactive at the time of presentation.

Table 1: Literature review of all cases of cutaneous mucinosis in the setting of dermatomyositis.

Author, year, diagnosis
Demographics
Clinical description
Pathology (skin biopsy)
Associated condition(s)
Therapy and course

Johnson et al., 1973 [8]
DM with lichen myxedematosus
35 African American males
Pruritic papular rash on upper and lower extremities, face, chest, and back. With perifollicular papules on forearms, hands, back, face and lower extremities, dysphagia and proximal muscle weakness of shoulders and pelvic girdle, and nail fold telangiectasia
Fragmented collagen with fibroblast proliferation and mucinous changes extending from the epidermis into the dermis with perivascular lymphocytosis and occasional histiocytes
None
80 mg oral prednisone daily with good response

Igarashi et al., 1985 [9]
DM with cutaneous mucinosis
67 Japanese males
Poikilodermatous lesions on face, chest, and extremities
Skin bx: frayed and fragmented collagen bundles with mucinous material in between bundles when stained with alcian blue
Gastric cancer
Unknown

Requena et al., 1990 [3]
DM with mucinosis
66 females
Erythematous, indurated plaque on hypogastric region of abdomen with irregular borders, heliotrope rash, violaceous rash on face, and Gottron’s papules.
Amorphous mucinous material in epidermis and dermis which stained with alcian blue. The mucinous deposition caused thickening of the dermis and separation of collagen fibers
None
80 mg oral prednisone and 120 mg oral azathioprine daily for 4 weeks with slow taper improved malaise and weakness however only partial improvement of the abdominal mucinous plaque

Kaufmann et al., 1998 [1]
Plaque like mucinosis
Case  1: 65 females
Case  1: erythematous plaques on extensor surface of upper extremities and left hip, muscle weakness of shoulder, and pelvic girdle
Case  1: separation of collagen bundles with perivascular lymphoplasmacytic infiltrate with abundant mucin deposition in the papillary and reticular dermis on staining with alcian blue
Case  1: none
Case  1: 80 mg oral prednisone daily, and 100 mg azathioprine daily with clinical response within 3 weeks, full resolution at 1 year

Case  2: 37 females
Case  2: erythematous plaques over lateral surface of thighs bilaterally, weakness in shoulder and pelvic girdle, and clinical picture developed after fever arthralgia and malaise
Case  2: skin biopsy-separation of collagen vascular bundles with superficial and deep perivascular lymphoplasmacytic infiltrate of dermis with mucin between separated collagen bundles on Alcian blue staining
Case  2: obesity, history of autoimmune thyroiditis, preceded by viral prodrome. No malignancy detected
Case  2: 2 days of IVIG and high dose prednisone and then azathioprine, with excellent response

Del Pozo et al., 2001 [2]
DM with cutaneous mucinosis
Case  1: 53 females
Case  1: small violaceous papules on upper extremities and chest; proximal muscle weakness
Case  1: skin biopsy showed hyperkeratosis, colloid bodies, and edema at the dermoepidermal junction with moderate perivascular lymphocytic infiltrate. Collagen bundles separated by mucin deposition
Case  1: ovarian adenocarcinoma
Case  1: recurrence despite prednisone, hydroxychloroquine, methotrexate, and azathioprine. Ovarian carcinoma treated with surgery, paclitaxel and cisplatin, no comment on status of DM or cutaneous findings after treatment

Case  2: 44 females
Case  2: flesh coloured papules across flexural creases of palms and fingers
Case  2: skin biopsy-epidermal atrophy with perivascular lymphocytic infiltrate and moderate mucin deposition between collagen fibers
Case  2: none
Case  2: mucinosis developed after treatment for DM with 30 mg prednisone po and 250 mg hydroxychloroquine daily, lesions did not improve with this treatment

Tan et al., 2003 [7]
DM with cutaneous mucinosis
65 Chinese males
Nontender erythematous plaques on neck, upper back and extensor surfaces of forearms bilaterally.
Proximal muscle weakness developed 3 months after initial presentation
Mucin deposition between collagen bundles with surrounding superficial perivascular lymphocytic infiltrate without epidermal changes
Nasopharyngeal carcinoma
Skin lesions resolved after 2 months of radiation therapy

Chen et al., 2005 [10]
Dermatomyositis with mucinosis and intestinal vasculopathy
21 Taiwanese females
Erythematous indurated mass on lower abdomen, labia majora and inner thigh with malar rash and periungual telangiectasia, heliotrope rash, Gottron’s papules, proximal muscle weakness, and dysphagia
Atrophic epidermis with vacuolar alteration of basal keratinocytes, interstitial mucin deposition, and perivascular lymphocytic infiltrate of dermis and subcutaneous tissue
None
Prednisolone 60 mg/d IV with resolution of CPK however developed dysphagia and pulse steroid therapy initiated. Patient suffered complications and ultimately died after a long hospital course

Edward et al., 2007 [11]
Amyopathic DM with mucinosis
31-year-old female
Puritic rash on flexor surface of forearms and chest, violaceous rash of face, Gottron’s papules, and nail fold telangiectasia
Dermal accumulation of mucin without inflammatory infiltrate; no evidence of inflammatory myopathy
None
Improved with oral steroids

Wang, 2011 [12]
DM with lichen myxedematosus
60-year-old male
Violaceous erythema on face, neck, and chest with flesh coloured papules on arms; muscle weakness of shoulders and dysphagia
Separation of collagen bundles with lymphocytic infiltrate of dermis and mucin deposition between collagen bundles demonstrated with alcian blue stain
None
Oral prednisone 40 mg daily with good response

Overall, clinical cutaneous manifestations of mucinous rashes are diverse: Chen, Requena, and Kaufmann describe plaque like skin changes, whereas Wang describes the rash as violaceous; Del Pozo and Johnson describe a distinctly papular rash. Most papers reported classic cutaneous findings of DM alongside the mucinous findings, with Gottron’s papules and a heliotrope rash being common. Our patient had the most diffuse mucinous rash of the cases reported, involving the face, chest, back, and all extremities.

In the majority of cases, cutaneous symptoms preceded or occurred simultaneous to muscle weakness. Del Pozo et al. describe mucinous skin changes occurring four years after presentation and treatment of DM, and this is one of two cases where the mucinous skin changes did not resolve [2, 3]. In general, cutaneous lesions of mucinosis in the setting of DM seem to respond well to treatment when they appear in the early stages of disease. The majority of patients improved with oral steroids ± azathioprine, with resistant cases improving with IVIG [1]. Only one case did not describe improvement in cutaneous mucinosis despite lack of evidence of malignancy; in this case the mucinosis developed after DM had been successfully treated and did not respond to first line treatment [2]. One case was fatal due to respiratory complications of DM and recurrent infection due to long-term high dose steroid use [10]. Of note, in the latter two cases IVIG was not utilized per case documentation.

3.2. Dermatomyositis and Malignancy

DM has a clear temporal link with malignancy. Cancer may present in 15–30% of the adults with DM prior to or at diagnosis or during follow up. DM is most commonly associated with ovarian, breast, lung and colon cancer, melanoma, and non-Hodgkins lymphoma, with adenocarcinomas accounting for 70% of all associated tumors [19]. The pathophysiology relating DM and malignancy is unproven, but the leading proposed hypothesis is that of an autoimmune paraneoplastic mechanism. Myositis specific antigens (MSA), such as antisynthetase and antisignal recognition particle, have been shown to be expressed at low levels by normal muscles cells and are over expressed during regeneration of muscle fibers during DM [20]. A tumor may overexpress oncoproteins or antigens similar to the myositis antigens, which subsequently stimulate the immune system leading to a lymphocytic reaction causing autoantibody deposition and damage to myofibers [21–23]. Casiola-Rosen showed that solid tumors such as breast and lung may express exact MSA antigens. The damage to muscles causes a release of antigens from the muscle fibers themselves further sensitizing the immune system to the striated muscle. This theory is complemented by the previous theories discussed, correlating serologic antibody titers with DM activity.

As noted previously, malignancy was associated with DM and cutaneous mucinosis in 3 of the 12 cases in the English literature. This proportion of cases with cutaneous mucinosis related to malignancy is proportionate to the number of DM cases relating to malignancy reported in the literature generally (30%). It is unlikely that the cutaneous mucinosis is independently related to malignancy or that the presence of malignancy increases the chance of cutaneous mucinosis expressed in DM.

4. Conclusion

To date there are 12 cases describing macroscopically evident cutaneous mucin in DM. Our case describes a middle aged man with NSCLC in remission presenting with a puritic, diffuse, and violaceous rash. Histologic evidence showed mucin deposition in the dermis without dermal thickening alongside clinical, immunoserologic, and MRI findings consistent with DM, and even though our patient also had serologies suggestive of systemic lupus erythematosus, the predominant clinical picture was that of DM. The patient’s cutaneous findings were highly resistant to first and second line treatments and only improved with the initiation of IVIG. While mucin deposition is a common microscopic finding in connective tissue diseases, it is rarely seen macroscopically. The pathophysiologic mechanism of cutaneous mucin production in these clinical scenarios is unclear. The link between hypoxic states and mucin deposition is a new concept, which has not been explored in the setting of dermatomyositis. Of the cases of cutaneous mucinosis and DM in the literature, the majority of cases improved with first line treatment for DM and in resistant cases positive results were seen using IVIG.

Conflict of Interests

The authors declare that there is no conflict of interests regarding to the publication of this paper.

References

R. Kaufmann, D. Greiner, P. Schmidt, and M. Wolter, “Dermatomyositis presenting as plaque-like mucinosis,” British Journal of Dermatology, vol. 138, no. 5, pp. 889–892, 1998.

J. Del Pozo, M. Almagro, W. Martínez, et al., “Dermatomyositis and mucinosis,” International Journal of Dermatology, vol. 40, no. 2, pp. 120–124, 2001.

L. Requena, A. Aquilar, and Y. E. Sanchez, “A corrugated plaque on the abdominal wall. Cutaneous mucinosis secondary to dermatomyositis,” Archives of Dermatology, vol. 126, no. 12, pp. 1639–1640, 1990.

A. M. Shekari, M. Ghiasi, E. Ghasemi, and Z. A. Kani, “Papulonodular mucinosis indicating systemic lupus erythematosus,” Clinical and Experimental Dermatology, vol. 34, no. 8, pp. e558–e560, 2009.

M. Allam and M. Ghozzi, “Scleromyxedema: a case report and review of the literature,” Case Reports in Dermatology, vol. 5, no. 2, pp. 168–175, 2013.

M. C. Dalakas, “Pathophysiology of inflammatory and autoimmune myopathies,” Presse Medicale, vol. 40, no. 4, pp. e237–e247, 2011.

E. Tan, S. H. Tan, and S. K. Ng, “Cutaneous mucinosis in dermatomyositis associated with a malignant tumor,” Journal of the American Academy of Dermatology, vol. 48, no. 5, pp. S41–S42, 2003.

B. L. Johnson, I. R. Horowitz, C. R. Charles, and D. L. Cooper, “Dermatomyositis and lichen myxedematosus: a clinical, histopathological and electron microscopic study,” Dermatologica, vol. 147, no. 2, pp. 109–122, 1973.

M. Igarashi, H. Aizawa, Y. Tokudome, and H. Tagami, “Dermatomyositis with prominent mucinous skin change. Histochemical and biochemical aspects of glycosaminoglycans,” Dermatologica, vol. 170, no. 1, pp. 6–11, 1985.

G.-Y. Chen, M.-F. Liu, J. Y.-Y. Lee, and W. Chen, “Combination of massive mucinosis, dermatomyositis, pyoderma gangrenosum-like ulcer, bullae and fatal intestinal vasculopathy in a young female,” European Journal of Dermatology, vol. 15, no. 5, pp. 396–400, 2005.

M. Edward, L. Fitzgerald, C. Thind, J. Leman, and A. D. Burden, “Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum,” British Journal of Dermatology, vol. 156, no. 3, pp. 473–479, 2007.

S. Wang, “Annular lichen myxedematosus in a patient with dermatomyositis,” International Journal of Dermatology, vol. 50, no. 3, pp. 370–372, 2011.

J. T. Kissel, J. R. Mendell, and K. W. Rammohan, “Microvascular deposition of complement membrane attack complex in dermatomyositis,” The New England Journal of Medicine, vol. 314, no. 6, pp. 329–334, 1986.

F. Rongioletti and A. Rebora, “Cutaneous mucinoses: microscopic criteria for diagnosis,” The American Journal of Dermatopathology, vol. 23, no. 3, pp. 257–267, 2001.

A. G. Pandya, R. D. Sontheimer, C. J. Cockerell, A. Takashima, and M. Piepkorn, “Papulonodular mucinosis associated with systemic lupus erythematosus: possible mechanisms of increased glycosaminoglycan accumulation,” Journal of the American Academy of Dermatology, vol. 32, no. 2, pp. 199–205, 1995.

R. Pugashetti, D. C. Zedek, E. V. Seiverling, P. Rajendran, and T. Berger, “Dermal mucinosis as a sign of venous insufficiency,” Journal of Cutaneous Pathology, vol. 37, no. 2, pp. 292–296, 2010.

K. Hashimoto, K. Fukuda, K. Yamazaki et al., “Hypoxia-induced hyaluronan synthesis by articular chondrocytes: the role of nitric oxide,” Inflammation Research, vol. 55, no. 2, pp. 72–77, 2006.

M. C. Dalakas, “Inflammatory myopathies: management of steroid resistance,” Current Opinion in Neurology, vol. 24, no. 5, pp. 457–462, 2011.

S. M. Levine, “Cancer and myositis: new insights into an old association,” Current Opinion in Rheumatology, vol. 18, no. 6, pp. 620–624, 2006.

L. Casciola-Rosen, K. Nagaraju, P. Plotz et al., “Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy,” Journal of Experimental Medicine, vol. 201, no. 4, pp. 591–601, 2005.

S. Zampieri, M. Valente, N. Adami et al., “Polymyositis, dermatomyositis and malignancy: a further intriguing link,” Autoimmunity Reviews, vol. 9, no. 6, pp. 449–453, 2010.

A. Chakroun, J. Guigay, A. Lusinchi, P. Marandas, F. Janot, and D. M. Hartl, “Paraneoplastic dermatomyositis and nasopharyngeal carcinoma: diagnosis, treatment and prognosis,” Annales Francaises d'Oto-Rhino-Laryngologie et de Pathologie Cervico-Faciale, vol. 128, no. 3, pp. 148–152, 2011.

P. Ungprasert, N. K. Bethina, and C. H. Jones, “Malignancy and idiopathic inflammatory myopathies,” North American Journal of Medical Sciences, vol. 5, no. 10, pp. 569–572, 2013.